<DOC>
	<DOCNO>NCT03082222</DOCNO>
	<brief_summary>This non interventional prospective study . Centers enroll adult participant partial onset seizure without secondary generalisation clinician decide initiate ESL adjunctive therapy prior decision take part study . Participants enrol study receive eslicarbazepine acetate ( ESL ) either adjunctive therapy one baseline antiepileptic drug ( AED ) least two baseline AEDs . Participants see baseline follow-up visit approximately 6 month assess retention , efficacy , tolerability , quality life ( optional ) , cognitive performance ( optional ) .</brief_summary>
	<brief_title>ZEDEBAC : Zebinix Effects Dependency Baseline Conditions</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>1 . Partial onset seizure without secondary generalisation conjunction diagnose epilepsy symptomatic unknown course . 2 . Treatment least one antiepileptic drug ( AED ) license Germany . 3 . The decision prescribe Eslicarbazepine acetate ( ESL ) take independent prior enrollment study . 4 . Treatment ESL agreement valid summary product characteristic ( SmPC ) version , particularly license indication . 5 . Age 18 year old . 6 . Participant 's write consent . 1 . Known psychogenic nonepileptic attack . 2 . Participation interventional study . 3 . Previous enrollment current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>partial onset seizure</keyword>
	<keyword>secondary generalization</keyword>
</DOC>